Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAK: CGT9486 + sunitinib versus sunitinib in advanced gastrointestinal stromal tumors
2022-500637-80-00Phase 3Authorised
- Sponsor
- Cogent Biosciences
- Start
- Mar 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing CGT9486 + sunitinib with sunitinib (2 arms). Primary endpoint: Progression-free survival. Planned start Mar 2023; status: authorised.
02
Drugs
bezuclastinibsunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2022-500637-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500637-80-00.